Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Aumolertinib Combined Ommaya Reservoir Intrathecal Chemotherapy With Pemetrexed for Leptomeningeal Metastasis From EGFR-mutated NSCLC and Investigate the Efficacy Prognostic Value of Dynamic Changes of cfDNA

NCT05810350 is registered in ClinicalTrials.gov with Three Gorges Hospital of Chongqing University as lead sponsor.

NCT NCT05810350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05810350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Aumolertinib Combined Ommaya Reservoir Intrathecal Chemotherapy With Pemetrexed for Leptomeningeal Metastasis From EGFR-mutated NSCLC and Investigate the Efficacy Prognostic Value of Dynamic Changes of cfDNA
Lead sponsor
Three Gorges Hospital of Chongqing University
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2023
Completion date
August 31, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer